

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
04 November 2021 (04.11.2021)



(10) International Publication Number
WO 2021/218862 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) C12N 15/13 (2006.01)
C07K 16/46 (2006.01) A61K 39/395 (2006.01)

(21) International Application Number:

PCT/CN2021/089649

(22) International Filing Date:

25 April 2021 (25.04.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2020/087036
26 April 2020 (26.04.2020) CN
PCT/CN2021/073085
21 January 2021 (21.01.2021) CN
PCT/CN2021/085181
02 April 2021 (02.04.2021) CN

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(71) Applicant: **BIOCYTOGEN PHARMACEUTICALS**

(**BEIJING**) **CO., LTD** [CN/CN]; No. 12, Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing 102600 (CN).

(72) Inventors: **GUO, Yuan**; No. 12, Baoshen South Street,

Daxing Bio-Medicine Industry Park, Daxing District, Beijing 102600 (CN). **LIU, Baihong**; No. 12, Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing 102600 (CN). **YANG, Yi**; No. 12, Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing 102600 (CN). **SHEN, Yuele**; No. 12, Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing 102600 (CN).

(74) Agent: **BEIJING LINKTEC IP LAW FIRM (SPECIAL**

GENERAL PARTNERSHIP); 12B17, 12th Floor, Building 1, Courtyard 13, Dazhongsi, Haidian District, Beijing 100098 (CN).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: MODIFIED IMMUNOGLOBULINS

(57) Abstract: The present invention provide a polypeptide complex comprising: a first polypeptide comprising a first CH3 domain, a second polypeptide comprising a second CH3 domain, wherein a third polypeptide is fused to the first CH3 domain. A pharmaceutical composition comprising the polypeptide and methods of making the polypeptide complex.

WO 2021/218862 A1